JP6894846B2 - Ｈｉｖ融合体を標的とするポリペプチド - Google Patents

Ｈｉｖ融合体を標的とするポリペプチド Download PDF

Info

Publication number
JP6894846B2
JP6894846B2 JP2017555557A JP2017555557A JP6894846B2 JP 6894846 B2 JP6894846 B2 JP 6894846B2 JP 2017555557 A JP2017555557 A JP 2017555557A JP 2017555557 A JP2017555557 A JP 2017555557A JP 6894846 B2 JP6894846 B2 JP 6894846B2
Authority
JP
Japan
Prior art keywords
amino acid
adnectin
polypeptide
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017555557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516247A5 (https=
JP2018516247A (ja
Inventor
クリスタル，マーク，アール．
ウェンセル，デイビッド，エル．
デイビス，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2018516247A publication Critical patent/JP2018516247A/ja
Publication of JP2018516247A5 publication Critical patent/JP2018516247A5/ja
Application granted granted Critical
Publication of JP6894846B2 publication Critical patent/JP6894846B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
JP2017555557A 2015-04-24 2016-04-14 Ｈｉｖ融合体を標的とするポリペプチド Expired - Fee Related JP6894846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US62/152,271 2015-04-24
US201562257474P 2015-11-19 2015-11-19
US62/257,474 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020174288A Division JP2021035951A (ja) 2015-04-24 2020-10-16 Ｈｉｖ融合体を標的とするポリペプチド

Publications (3)

Publication Number Publication Date
JP2018516247A JP2018516247A (ja) 2018-06-21
JP2018516247A5 JP2018516247A5 (https=) 2019-04-25
JP6894846B2 true JP6894846B2 (ja) 2021-06-30

Family

ID=55809237

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017555557A Expired - Fee Related JP6894846B2 (ja) 2015-04-24 2016-04-14 Ｈｉｖ融合体を標的とするポリペプチド
JP2020174288A Pending JP2021035951A (ja) 2015-04-24 2020-10-16 Ｈｉｖ融合体を標的とするポリペプチド
JP2023014947A Active JP7465378B2 (ja) 2015-04-24 2023-02-03 Ｈｉｖ融合体を標的とするポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020174288A Pending JP2021035951A (ja) 2015-04-24 2020-10-16 Ｈｉｖ融合体を標的とするポリペプチド
JP2023014947A Active JP7465378B2 (ja) 2015-04-24 2023-02-03 Ｈｉｖ融合体を標的とするポリペプチド

Country Status (25)

Country Link
US (2) US10407490B2 (https=)
EP (2) EP3985020A1 (https=)
JP (3) JP6894846B2 (https=)
KR (1) KR20170138558A (https=)
CN (1) CN107922474A (https=)
AU (2) AU2016252008B2 (https=)
BR (1) BR112017022790A2 (https=)
CA (1) CA2983276A1 (https=)
CL (1) CL2017002687A1 (https=)
CO (1) CO2017011583A2 (https=)
CR (1) CR20170482A (https=)
DO (1) DOP2017000246A (https=)
EA (1) EA035332B1 (https=)
ES (1) ES2884267T3 (https=)
HK (1) HK1243432A1 (https=)
IL (1) IL255122A0 (https=)
MA (2) MA56222A (https=)
MX (1) MX2017013687A (https=)
PE (1) PE20180162A1 (https=)
PH (1) PH12017501914A1 (https=)
PT (1) PT3286212T (https=)
SG (1) SG11201708441RA (https=)
TW (1) TW201643185A (https=)
UY (1) UY36650A (https=)
WO (1) WO2016171980A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
CN108997482B (zh) * 2018-08-09 2025-09-09 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1543166A4 (en) * 2002-09-27 2009-10-28 Genentech Inc SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
JP2011507543A (ja) 2007-12-27 2011-03-10 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
PL2274331T3 (pl) 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
BRPI0919881B1 (pt) * 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
EA022983B1 (ru) * 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
JP2014504587A (ja) * 2010-12-22 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー Ｉｌ−２３に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質
AU2012260434A1 (en) * 2011-05-23 2013-10-31 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EP2761066B1 (en) * 2011-09-27 2018-12-05 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
EP2951206A2 (en) * 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Also Published As

Publication number Publication date
TW201643185A (zh) 2016-12-16
SG11201708441RA (en) 2017-11-29
BR112017022790A2 (pt) 2018-07-17
JP2021035951A (ja) 2021-03-04
HK1243432A1 (zh) 2018-07-13
KR20170138558A (ko) 2017-12-15
CN107922474A (zh) 2018-04-17
JP2023055875A (ja) 2023-04-18
AU2016252008B2 (en) 2019-06-13
UY36650A (es) 2016-11-30
JP7465378B2 (ja) 2024-04-10
EP3286212B1 (en) 2021-06-02
AU2019226255A1 (en) 2019-09-26
CL2017002687A1 (es) 2018-04-20
US20190359688A1 (en) 2019-11-28
EP3286212A1 (en) 2018-02-28
MA41943A (fr) 2018-02-28
MA56222A (fr) 2022-04-20
CO2017011583A2 (es) 2018-04-19
MX2017013687A (es) 2018-07-06
DOP2017000246A (es) 2018-01-31
US11155602B2 (en) 2021-10-26
JP2018516247A (ja) 2018-06-21
CA2983276A1 (en) 2016-10-27
US10407490B2 (en) 2019-09-10
EP3985020A1 (en) 2022-04-20
US20180111980A1 (en) 2018-04-26
EA035332B1 (ru) 2020-05-28
CR20170482A (es) 2018-03-07
PH12017501914A1 (en) 2018-03-05
IL255122A0 (en) 2017-12-31
AU2016252008A1 (en) 2017-11-09
ES2884267T3 (es) 2021-12-10
WO2016171980A1 (en) 2016-10-27
PE20180162A1 (es) 2018-01-18
PT3286212T (pt) 2021-08-24
EA201792269A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
JP7465378B2 (ja) Ｈｉｖ融合体を標的とするポリペプチド
US20210122805A1 (en) Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
EP3365366B1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
TWI694085B (zh) 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
TW201130501A (en) Fibronectin based scaffold domain proteins that bind IL-23
JP2014510518A (ja) Ｈｓａ関連組成物および使用方法
TW201000118A (en) Multivalent fibronectin based scaffold domain proteins
US20110263485A1 (en) Bifunctional Griffithsin Analogs
US20240239877A1 (en) Antigen binding polypeptides
CN118510536A (zh) 松弛素-2融合蛋白类似物及其使用方法
WO2020077297A1 (en) Methods and compositions for treatment of protein aggregation-based disorders
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190909

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201016

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201023

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210604

R150 Certificate of patent or registration of utility model

Ref document number: 6894846

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees